Thymosin Beta-4
43-Amino Acid Regenerative Peptide | Tissue Repair & Healing
Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide that plays a crucial role in tissue repair, wound healing, and cellular regeneration. It promotes angiogenesis, reduces inflammation, and supports the migration and differentiation of various cell types involved in healing processes.
Daily dose
1.6-42 mg
Frequency
Daily to weekly
Cycle length
2-12 weeks
Storage
2-8°C
Key benefits
Systemic regenerative effects, proven clinical efficacy, optimal bioavailability for tissue repair
How it works
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects
Dosage protocols
Goal
Acute Wound Healing
Dose
1.6 mg · Daily
Route
Subcutaneous injection
Goal
Cardiac Protection
Dose
42 mg · Single dose
Route
IV bolus within 6 hours of MI
Goal
Chronic Tissue Repair
Dose
6 mg · Twice weekly
Route
Subcutaneous injection
Goal
Neurological Recovery
Dose
30 mg · Three times over 72 hours
Route
IV infusion
Goal
General Regeneration
Dose
2-5 mg · Daily or every other day
Route
Subcutaneous injection
Goal
Research Protocol
Dose
0.6-14 mg · As per study design
Route
SC or IV as indicated
Research indications
tissue Repair
cardiovascular
neuroprotection
Administration
Interactions
Safety notes
Monitor injection sites for local reactions or inflammation
Use sterile technique to prevent infection at injection sites
Start with lower doses to assess individual tolerance
Discontinue if signs of allergic reaction or unusual side effects
Research studies
Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients (2016)
Humans | EPC pre-treatment with Tβ4 | Single transplantation | Improved cardiac function compared to control
First human study of Thymosin β4 in heart attack patients, demonstrating potential clinical benefits in repairing damaged tissue and improving cardiac function.
View study →Phase II Dry Eye Clinical Trial Using Controlled Adverse Environment Model (2015)
Humans | 0.1% topical drops | 28 days | Significant improvement in symptoms and corneal staining
Randomized, double-masked, placebo-controlled study in 72 subjects showing significant positive effects on ocular discomfort and corneal staining with excellent safety profile.
View study →Phase I Human Safety Study: Intravenous Thymosin β4 (2010)
Humans | 42-1260 mg IV | Single and multiple doses | Excellent safety profile, no dose-limiting toxicity
First-in-human randomized, placebo-controlled study establishing safety and pharmacokinetics of IV Thymosin β4 administration in healthy volunteers.
View study →Neurotrophic Keratopathy Compassionate Use Trial (2010)
Humans | 0.1% topical drops | Up to several months | 6 of 9 subjects achieved complete healing
Physician-sponsored compassionate use trial using RGN-259 formulation showing complete clearing of persistent corneal defects in most subjects.
View study →Venous Ulcer European Clinical Trial (2007)
Humans | Topical application | 84 days treatment | Safety and healing enhancement evaluation
Double-blind, placebo-controlled, dose-escalation study across 10 European sites evaluating safety, tolerability, and healing enhancement in venous ulcer patients.
View study →Pressure Ulcer Clinical Investigation
Humans | Topical application | Phase 2 study | Accelerated wound healing demonstrated
Clinical investigation of topical Thymosin β4 in pressure ulcer patients showing accelerated healing rates compared to standard care.
View study →